• Bhubaneswar India
  • Contact+ 91-9938772605
  • Mon - Sat : 10:00AM - 6:00PM

Tag: StoxBox

StoxBox Top 3 Investment Picks for Big Gains

2nd September 2024: Discover StoxBox’s top 3 investment picks designed to capitalize on market trends and deliver exceptional returns. From promising technical setups to solid fundamental strength, these recommendations offer lucrative opportunities to enhance your portfolio. Dive into the details and make informed investment choices today!

1) Power Finance Corporation (PFC )

Power Finance Corporation Ltd. (PFC), currently trading at a market price of 539, is set for a promising investment opportunity. StoxBox recommends a target price of 600 and suggests a stop loss at 507, with a strategic time frame of 2 months. Established in 1986 and owned by the Ministry of Power, Government of India, PFC plays a vital role as the financial backbone of the Indian power sector.

Following a profit booking at its highs of 580, PFC has retraced to a key demand zone around 480, where significant buying interest has emerged. This sets the stage for a compelling rebound. With its established market position and strong fundamentals, PFC offers an attractive risk-reward profile, making it a standout choice for investors looking to capitalize on a potential uptrend.

2) Wipro

Wipro Ltd., trading at 535, is poised for growth with a target price of 612 and a stop loss at 508 over 2 months. As a global leader in IT and consulting, Wipro is showing a classic cup and handle pattern, indicating a trend reversal and growth potential. With the stock reclaiming its 50-day moving average as strong support, Wipro offers a low-risk, high-reward opportunity for investors looking to benefit from its next growth phase.

3) Welspun Living

StoxBox recommends Welspun Living as an attractive investment option, currently trading at 208 with a target price of 245 over a 1-year period. A major player in the global home textiles market, Welspun Living is well-positioned for robust long-term growth. The company’s extensive product portfolio and strong distribution network enable it to capitalize on industry tailwinds, including PLI schemes and the China +1 strategy. Despite geopolitical challenges, Welspun Living’s strategic focus on green energy and a significant 48% debt reduction since FY20 highlight its financial strength. Welspun Living’s commitment to sustainable growth makes it a prime candidate for delivering solid returns over the next year.

StoxBox’s recommendations blend technical insights with strong fundamental analysis, offering investors well-rounded opportunities to enhance their portfolios. Consider these picks for a strategic advantage in your investment journey.

StoxBox: Buy Aarti Drugs for 16percentage Upside

StoxBox has issued a “Buy” rating for Aarti Drugs Limited, projecting a target price of INR 602, reflecting a 16% upside from the current market price (CMP). This recommendation is based on a valuation of 23x FY26e earnings and highlights the company’s solid growth prospects over the next 12 months.

stoxbox

According to Manish Chowdhury, Head of Research at StoxBox, “Aarti Drugs is strategically positioned in the pharmaceutical industry with its extensive portfolio of over 50 compounds. The company’s significant presence in key therapeutic segments and its robust global footprint underscore its potential for substantial growth. Our target price of INR 602 reflects our confidence in Aarti Drugs’ ability to capitalize on its innovative capabilities and operational strengths.”

Aarti Drugs, a global pharmaceutical company, generates 33% of its revenue from exports, with major markets being North America, Latin America, and Africa. The company operates nine manufacturing plants in Tarapur and two in Sarigam, adhering to stringent quality standards and regulatory approvals. Aarti Drugs’ revenue has grown at an 8.8% CAGR from FY2020-24, with diversified revenue streams including anti-biotics, anti-protozoal, and anti-diabetics. Recent capacity expansions and new product launches are expected to boost revenue by INR 400-500 crores over the next three years.

Manish adds: “With ongoing capacity expansions and strategic new product launches, Aarti Drugs is well-positioned to enhance its market share and operational efficiency. The company’s focus on innovation and its expansive global market presence provides a solid foundation for achieving our projected growth targets.”

With a strong track record, significant capital expenditure plans, and a focus on expanding its product offerings and export markets, Aarti Drugs is well-positioned for future growth.

StoxBox’s 7 Stock Picks: Elevate Your Portfolio Today

In the fast-paced world of stock markets, making well-informed investment decisions can greatly improve your portfolio’s performance. StoxBox has once again showcased its expertise with its latest “Techno Funda” report, revealing the top seven stocks for investment. This carefully curated list combines both technical and fundamental analysis to identify stocks with strong growth potential. Let’s delve into the details of these promising investments.

1) HDFC Asset Management

– HDFC Asset Management Company (HDFCAMC) is currently priced at ₹4125, with a target price of ₹4434 and a stop loss at ₹3967. StoxBox recommends buying this stock due to its strong upward momentum in DMA indicators and potential benefits from new product offerings and market expansion. The company’s focus on increasing its market share and positive sector outlook makes it a solid investment.

2) PAYTM

– One 97 Communications (PAYTM), priced at ₹417, has a target price of ₹449 and a stop loss of ₹398. Paytm has a large, engaged customer base and is expecting EBITDA breakeven by FY25. The stock has shown potential trend reversal patterns, making it a compelling buy at current levels.

3) Power Finance Corporation

– Power Finance Corporation (PFC) is priced at ₹531, with a target price of ₹572 and a stop loss at ₹506. PFC is experiencing strong weekly upward movement in its DMA indicators. The company’s robust financial performance and strategic positioning in the power sector contribute to its attractiveness as an investment.

4) Rural Electrification Corporation

– Rural Electrification Corporation (REC), priced at ₹562, has a target price of ₹606 and a stop loss of ₹537. REC is benefiting from favorable sector dynamics and strong financial health. The company’s continued growth and strategic initiatives make it a worthy addition to any investment portfolio.

5) Siemens

– Siemens with a current price of ₹7803, has a target price of ₹8464 and a stop loss at ₹7491. Siemens shows significant strength in its technical indicators with a positive sector outlook. The company’s innovative solutions and market leadership position it well for continued growth.

6) SUNTV

– Sun TV Network Ltd. (SUNTV), priced at ₹795, has a target price of ₹854 and a stop loss at ₹759. Sun TV Network is demonstrating strong technical patterns with upward trends in its DMA indicators.

7) Zomato

– Zomato priced at ₹208, has a target price of ₹225 and a stop loss of ₹197. Zomato is showing potential for upward movement supported by its inverse head-and-shoulder pattern, indicating a possible trend reversal. The company’s large user base and strategic initiatives in the food delivery sector enhance its investment appeal.

StoxBox Launches New Brand Campaign: “Brokerage Par Bandh Karo Kharch, Pay Only for Research

June 13, 2024, Mumbai — StoxBox, one of India’s leading value brokers and a subsidiary of BP Wealth, is thrilled to announce the launch of its groundbreaking brand campaign, “Brokerage Par Bandh Karo Kharch, Pay Only for Research.” This campaign is designed to address a critical issue highlighted by a recent SEBI study, which found that 90% of traders in the Indian stock market are losing money. By focusing on paying only for research, StoxBox aims to guide investors toward more informed and profitable trading decisions.

StoxBox

This innovative campaign features a series of three compelling videos, each emphasizing different aspects of unnecessary expenses that investors often face and how StoxBox can help them create wealth:

Brokerage Par Bandh Karo Kharch, Pay Only for Research“, this video challenges the traditional brokerage fee model, urging investors to stop overspending on brokerage fees and instead invest in high-quality research that can lead to better investment outcomes. It highlights the importance of making informed decisions through institution-grade research rather than paying for expensive brokerage services. The other films in this series focus on two other angles, that an investor or a trader faces on a daily basis “Tricky Pricing Par Bandh Karo Kharch, Pay Only for Research” and “Rumours Par Bandh Karo Kharch, Pay Only for Research”.

At StoxBox, through our benevolent business model, we believe that comprehensive research is the cornerstone of successful investing. Our research offerings through our flagship product StoxCalls, which covers in-depth market analysis and research-driven recommendations, all designed to help investors make informed decisions. By focusing on high-quality research, investors can avoid common pitfalls, identify lucrative opportunities, and ultimately, create lasting wealth.

“Through our new campaign, we are directly addressing the concerns of investors who are struggling with unnecessary fees and unreliable information,” said Vamsi Krishna, CEO of StoxBox. “Our goal is to empower them with top-notch research that leads to informed investment decisions and long-term financial success. At StoxBox, we are committed to helping our clients achieve their financial goals by providing the tools and insights they need to invest wisely.”

The campaign videos are available across various digital platforms to reach a broad audience, ensuring that investors from all backgrounds can benefit from this crucial message. With StoxBox, investors are not just saving money—they are investing in their future and improving their chances of success in the stock market.

StoxBox: Views on Sun Pharma Industries Ltd. Q4 FY24 Result

The pharma giant reported strong financial results in Q4FY24, supported by robust performance in the US and domestic markets. The revenue growth was majorly led by the US market in the March quarter, with the global speciality business continuing to increase its share in the overall revenues. The company’s two businesses surpassed $1 billion in annual sales in FY24, namely Global Specialty and Emerging Markets. This achievement of critical mass in key markets has been a testimony for several years. The company continues building a speciality portfolio and investing further to gain scale across businesses. The company’s API business continues to focus on increasing API supply for captive consumption of critical products. We will keenly eye the management commentary on new product launches, US formulations (including Taro), business growth, speciality R&D pipeline, and domestic business. Further, the company will actively look for other new investment avenues for growth across all business segments in the coming years.

Sun Pharma Industries Ltd. Q4FY24 Result First Cut – Net Profit Beats Street Estimates
Company reported revenue growth of 9.6% YoY / down 3.2% QoQ to Rs. 11,983 crores and was below market expectations of Rs. 12,233 crores.
Domestic formulations business grew 10.2% YoY, further aided by 10.9% and 12.5% annual growth in US formulations (including Taro) and Rest of World (ROW) markets, respectively.
Sun Pharma ranked no. 1 and holds an 8.5% market share of over Rs. 1,970 billion IPM, per AIOCD AWACS MAT March 2024 report. For Q4FY24, the company launched nine new products in the Indian market.
EBITDA increased 9.3% YoY / down 7.8% QoQ to Rs. 3,092 crores, while EBITDA margin stood at 25.8% (below 8bps YoY / down 128bps QoQ) in Q4FY24, mainly on account of an increase in employee cost (+10bps YoY) and other expenses (+342bps YoY).
Profit after Tax stood at Rs. 2,659 crores (up 34.1% YoY / up 3.8% QoQ) in Q4FY24, above market expectations of Rs. 2,441 crores. PAT margin rose to 22.2% versus 20.7% in the previous quarter.
R&D investments for Q4FY24 stood at Rs. 900 crores (7.5% of sales), compared to Rs. 825 crores in Q3FY23.
The company’s board has declared a final dividend of Rs. 5.0 per share for FY24.

StoxBox: Research on HCL Technologies

 D. K. Mudaraddi, Research Analyst, StoxBox on HCL Technologies Ltd. Q4 FY24.

HCL Tech’s Q4FY24 revenue was impacted heavily by the seasonal weakness in the software products business despite the reversal of furloughs and incremental revenues from telecom and entertainment segment contracts. Wage hikes and normalization of products and platforms segment margin led to a significant decline in margin underperforming its peers. Leakage in discretionary business has bottomed out for HCL Tech, but there are no signs of a pickup in discretionary spending. There have been no major large deal announcements by HCL Tech in Q4FY24 which is concerning considering that its peers were able to sign mega deal MOUs during the current weak demand environment. Commentary on ER&D, Tech and Telecom vertical performance, demand scenario going forward, and ramp-up of deal wins will be key monitorable going ahead.

HCL Technologies Ltd. Q4FY24 Result First Cut – A miss on all fronts; Revenue guidance trimmed

Reported revenue grew to Rs. 28,499 crores (up 0.2% QoQ / up 7.1% YoY) in rupee terms, marginally missing market estimates of Rs. 28,557 crores.
EBIT dropped 11% QoQ / up 3.9% YoY to Rs. 5,024 crores, missing market expectations of Rs. 6,364 crores. The EBIT margin contracted to 17.6% (down 221 bps QoQ / down 55 bps YoY).
Net income grew to Rs. 3,995 crores (down 8.2% QoQ / up 0.4% YoY), missing market estimates of Rs. 4,123 crores. The PAT margin contracted to 14% (down 128 bps QoQ / down 94 bps YoY).
LTM attrition continuing recent trends declined 40bps QoQ to 12.4% in Q4FY24.
Order book recorded for Q4FY24 stood at USD 2.29 billion.
The board of directors recommended a dividend of Rs. 18 per equity share.
HCL Tech reported a headcount of 227,481 employees as on March 31, 2024, with a net addition of 2,725 employees in Q4FY24.
For FY25, HCL Tech reduced revenue guidance to 3%-5% in CC terms from 5-5.5% projected earlier, while EBIT margin guidance was retained at 18-19%.

Disclaimer/Disclaimer: This press release serves for informational purposes only and does not constitute professional advice. Any reliance on the information provided is at the reader’s discretion.

 

StoxBox: Views on UltraTech Cement Q4 FY24 Result

UltraTech Cement showed robust profit growth owing to operating efficiency kicking in and lower energy costs, despite pricing pressure in the industry. Grey cement and white cement volumes recorded double digit growth amid robust demand environment. Lower power and fuel cost due to lower pet coke and coal prices offset the declining realisations. The quarter did not see sustained prices hikes which lead to pricing pressure and lower realisations. Going forward, the blackout out period due to election is expected to result in further price wars as companies try to sell-off inventory. During the quarter, strong growth was seen in north and central regions owing to growth in rural housing and ongoing government infrastructure. The company has planned for Rs. 9,500 crores capex for the next financial year, inline with its goal reaching 183.5 MTPA capacity by FY27. With market leadership and pan-India presence, we believe that the company is better placed than its peers to withstand the current headwinds and should be the first to recover once the tide turns, especially post-monsoon.

UltraTech Cement Ltd. – Q4FY24 Result First Cut – Performance beats estimates; Robust profit growth owing to operating efficiency and lower input costs

  •  UltraTech Cement reported revenue of Rs. 20,419 crores, up 21.9% QoQ / 9.4% YoY, led by continued demand for building materials and decreasing operating costs.
  • Domestic sales volume saw a growth of 30% QoQ / 11% YoY which stood at 33.91 MT. The company achieved good volume growth in domestic sales of grey cement and white cement. The consolidated sales volume stood at 35.08 MT.
  • Domestic sales of grey cement saw a growth of 11% YoY, owing to robust demand environment.
  • Company’s EBITDA grew 25% QoQ / 23% YoY to Rs. 4,250 crores due to lower input costs and increase in demand. Ultratech Cement recorded an EBITDA/tonne of Rs. 1,185 for its domestic operations, down 1.9% QoQ / up 10.5% YoY.
  • PAT increased 27% QoQ / 35% YoY to Rs. 2,259 crores which is the highest ever quarterly PAT and beat consensus estimates of around Rs. 2,000 crs.
  • Energy power and fuel expenses stood at Rs. 1,420/tonne which were down by 16% YoY and 3.8% QoQ. The reduction in costs can be attributed to lower coal and pet coke consumption and efficiency improvement during the quarter.
  • Logistics costs remained largely flat and did not show any movement on a quarterly basis. The lead time also remained flat at 400 kms in Q4FY24.
  • Raw material cost declined 4.75% QoQ but remained flat on yearly basis.
    Other costs were up 4% YoY, owing to higher brand building and CSR expenses. However, it decreased significantly on a sequential basis by 24% as operating benefit kicked in and seasonally low plant maintenance.
  • The company commissioned additional grey cement capacity for 7.8 MTPA, taking the total domestic capacity to 140.8 MTPA.
  • The board has recommended a dividend of Rs. 70 per equity share.

Disclaimer/Disclaimer: This press release serves for informational purposes only and does not constitute professional advice. Any reliance on the information provided is at the reader’s discretion.